var data={"title":"Neurofibromatosis type 2","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Neurofibromatosis type 2</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/contributors\" class=\"contributor contributor_credentials\">D Gareth Evans, MD, FRCP</a></dd><dt><span> </span>Section Editors:</dt><dd><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/contributors\" class=\"contributor contributor_credentials\">Jay S Loeffler, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/contributors\" class=\"contributor contributor_credentials\">Patrick Y Wen, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/contributors\" class=\"contributor contributor_credentials\">April F Eichler, MD, MPH</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Mar 16, 2018.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Neurofibromatosis type 2 (NF2) is a dominantly inherited syndrome that predisposes individuals to multiple tumors of the nervous system [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/1-3\" class=\"abstract_t\">1-3</a>]. The most common of these are bilateral vestibular schwannomas; intracranial and spinal meningiomas and spine tumors, including intrinsic ependymomas, are also a prominent component of this condition. Mutations in the NF2 gene, which produces merlin, a tumor suppressor, are responsible for this syndrome.</p><p>The molecular pathogenesis, clinical features, diagnosis, and patient management of NF2 are reviewed here. Neurofibromatosis type 1 (NF1) (von Recklinghausen's disease) and schwannomatosis are discussed separately. (See <a href=\"topic.htm?path=neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis\" class=\"medical medical_review\">&quot;Neurofibromatosis type 1 (NF1): Pathogenesis, clinical features, and diagnosis&quot;</a> and <a href=\"topic.htm?path=schwannomatosis\" class=\"medical medical_review\">&quot;Schwannomatosis&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">MOLECULAR PATHOGENESIS</span></p><p class=\"headingAnchor\" id=\"H3\"><span class=\"h2\">NF2 gene</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Neurofibromatosis type 2 (NF2) is consistently linked with abnormalities of the <em>NF2</em> gene, which is located on chromosome 22 [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/4\" class=\"abstract_t\">4</a>]. The <em>NF2</em> gene produces merlin, also known as schwannomin, a cell membrane-related protein that acts as a tumor suppressor [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/5,6\" class=\"abstract_t\">5,6</a>].</p><p>Detailed molecular testing will identify an abnormality in <em>NF2</em> in over 93 percent of families with multiple members affected with NF2 [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/7\" class=\"abstract_t\">7</a>]. For individuals thought to harbor a new de novo mutation, somatic mosaicism may prevent the molecular diagnosis from being established unless tumor tissue is analyzed [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/7-11\" class=\"abstract_t\">7-11</a>].</p><p>The development of schwannomas and other tumors requires inactivation of both <em>NF2</em> alleles, since tumors only develop in cells that have lost function of their normal <em>NF2</em> allele. Individuals with NF2 may inherit an abnormal <em>NF2</em> allele from a parent. Alternatively, a de novo mutation may take place after fertilization, resulting in a mosaic expression of two cell lines.</p><p class=\"headingAnchor\" id=\"H4\"><span class=\"h2\">Genotype phenotype correlation</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Within a family that includes multiple members with NF2, the phenotypic expression and natural history of the disease are similar. However, significant differences have been observed between families harboring different abnormalities of <em>NF2</em>.</p><p>Frameshift or nonsense mutations cause truncated protein expression, which have been associated with more severe manifestations of NF2; missense or inframe deletions have been associated with milder manifestations of disease. In an analysis of 268 patients in whom the <em>NF2</em> abnormality was characterized, abnormalities manifested as a truncated protein were associated with statistically significant younger age at diagnosis, a higher prevalence and proportion of meningiomas, spinal tumors, tumors of cranial nerves other than VIII [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/12\" class=\"abstract_t\">12</a>]. Patients with mutations causing truncated protein also had vestibular schwannomas at a younger age and had more cutaneous tumors. There is also a positional effect, with mutations in the later parts of the gene, especially exons 14 and 15, being associated with milder disease and fewer meningiomas [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/13\" class=\"abstract_t\">13</a>].</p><p>There is now also evidence that these differences have marked effects on life expectancy, with missense mutations being associated with the best life expectancy and truncating mutations in exons 2 to 13 having the poorest survival [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/14\" class=\"abstract_t\">14</a>].</p><p class=\"headingAnchor\" id=\"H5\"><span class=\"h1\">EPIDEMIOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Although neurofibromatosis type 2 (NF2) was originally thought to be extremely rare, the use of detailed clinical criteria to identify cases, the recognition that greater than one-half of cases represent de novo mutations and occur in the absence of a positive family history, as well as the use of molecular testing to identify mutations within the <em>NF2</em> gene, have led to increased recognition of this syndrome [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/1\" class=\"abstract_t\">1</a>]. Two large population-based studies, one from England and the other from Finland, found that the incidence may be as high as 1 in 25,000 [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/15-17\" class=\"abstract_t\">15-17</a>]. (See <a href=\"#H13\" class=\"local\">'Diagnosis'</a> below.)</p><p class=\"headingAnchor\" id=\"H6\"><span class=\"h1\">CLINICAL FEATURES</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Neurofibromatosis type 2 (NF2) is an autosomal dominant syndrome with multiple manifestations that is due to mutations in the <em>NF2 </em>gene. Patients typically present around 20 years of age.</p><p>The most frequent clinical features include:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Neurologic lesions [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/18-20\" class=\"abstract_t\">18-20</a>]</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Bilateral vestibular schwannomas, generally developing by 30 years of age &ndash; 90 to 95 percent</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Schwannomas of other cranial nerve &ndash; 24 to 51 percent</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Intracranial meningiomas 45 to 77 percent [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/13\" class=\"abstract_t\">13</a>]</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Spinal tumors (both intramedullary and extramedullary) 63 to 90 percent</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Peripheral neuropathy &ndash; Up to 66 percent</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Eye lesions [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/21-23\" class=\"abstract_t\">21-23</a>]</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Cataracts &ndash; 60 to 81 percent</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Epiretinal membranes &ndash; 12 to 40 percent</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Retinal hamartomas &ndash; 6 to 22 percent</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Skin lesions [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/18,20,24,25\" class=\"abstract_t\">18,20,24,25</a>]</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Cutaneous tumors &ndash; 59 to 68 percent</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Skin plaques &ndash; 41 to 48 percent</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Subcutaneous tumors &ndash; 43 to 48 percent</p><p/><p>Children diagnosed with NF2 often have an atypical, but more severe, presentation [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/26\" class=\"abstract_t\">26</a>].</p><p class=\"headingAnchor\" id=\"H7\"><span class=\"h2\">Vestibular schwannomas</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Vestibular schwannomas in NF2 are typically bilateral and cause tinnitus, hearing loss, and balance dysfunction [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/2\" class=\"abstract_t\">2</a>]. The onset of hearing loss is usually gradually progressive and leads to deafness, although sudden hearing loss can occur. NF2-related vestibular schwannomas are usually multifocal and occur equally on the superior and inferior vestibular nerve [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/27\" class=\"abstract_t\">27</a>].</p><p>The mechanism of hearing loss from vestibular schwannomas in NF2 is not well understood, and there is poor correlation between tumor size <span class=\"nowrap\">and/or</span> growth rate and degree of hearing loss [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/28-31\" class=\"abstract_t\">28-31</a>]. One proposed mechanism is the accumulation of intralabyrinthine protein as a result of cochlear aperture obstruction, which can be visualized by high-resolution magnetic resonance imaging (MRI) [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/32\" class=\"abstract_t\">32</a>]. If left untreated, vestibular schwannomas can extend medially and cause brainstem compression and hydrocephalus. (See <a href=\"topic.htm?path=vestibular-schwannoma-acoustic-neuroma#H4\" class=\"medical medical_review\">&quot;Vestibular schwannoma (acoustic neuroma)&quot;, section on 'Clinical presentation'</a>.)</p><p>Almost all vestibular schwannomas in patients with NF2 are benign. However, they are an important cause of morbidity because of their anatomic location and bilaterality.</p><p class=\"headingAnchor\" id=\"H8\"><span class=\"h2\">Meningiomas</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Approximately one-half of individuals with NF2 have meningiomas, and multiple meningiomas are often present [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/33\" class=\"abstract_t\">33</a>]. The incidence increases with age, and lifetime risk may be as high as 75 percent [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/20\" class=\"abstract_t\">20</a>]. Most meningiomas are intracranial, although intradural, extramedullary spinal meningiomas are also seen. (See <a href=\"topic.htm?path=epidemiology-pathology-clinical-features-and-diagnosis-of-meningioma#H12\" class=\"medical medical_review\">&quot;Epidemiology, pathology, clinical features, and diagnosis of meningioma&quot;, section on 'Clinical presentation'</a> and <a href=\"topic.htm?path=spinal-cord-tumors#H16\" class=\"medical medical_review\">&quot;Spinal cord tumors&quot;, section on 'Meningioma'</a>.)</p><p>Patients with NF2 tend to develop meningiomas at an earlier age than those with sporadic meningiomas. When meningiomas are diagnosed during childhood, approximately 20 percent will be found to have NF2 [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/26,34\" class=\"abstract_t\">26,34</a>]. The meningiomas seen in patients with NF2 are more frequently atypical or anaplastic compared with sporadic tumors [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/35,36\" class=\"abstract_t\">35,36</a>]. Meningiomas are less frequent with mutations of any type after exon 12 [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/13\" class=\"abstract_t\">13</a>].</p><p class=\"headingAnchor\" id=\"H9\"><span class=\"h2\">Spinal tumors</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Most individuals with NF2 eventually develop a spinal tumor, which can cause debilitating pain, muscle weakness, or paresthesias [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/2,37,38\" class=\"abstract_t\">2,37,38</a>].</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Schwannomas are most common. These arise from the dorsal root and can take on a characteristic dumbbell shape. (See <a href=\"topic.htm?path=spinal-cord-tumors#H2\" class=\"medical medical_review\">&quot;Spinal cord tumors&quot;, section on 'Presentation'</a> and <a href=\"topic.htm?path=intradural-nerve-sheath-tumors#H9\" class=\"medical medical_review\">&quot;Intradural nerve sheath tumors&quot;, section on 'Clinical presentation'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Meningiomas can also arise on the spinal cord in the extramedullary space. (See <a href=\"topic.htm?path=spinal-cord-tumors#H16\" class=\"medical medical_review\">&quot;Spinal cord tumors&quot;, section on 'Meningioma'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Intramedullary tumors, particularly ependymomas, are seen in 5 to 33 percent of cases. (See <a href=\"topic.htm?path=spinal-cord-tumors#H8\" class=\"medical medical_review\">&quot;Spinal cord tumors&quot;, section on 'Ependymomas'</a>.)</p><p/><p class=\"headingAnchor\" id=\"H10\"><span class=\"h2\">Neuropathies</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Neuropathies can be manifested in a variety of ways in individuals with NF2 [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/1\" class=\"abstract_t\">1</a>]. Some people develop a mononeuropathy, often involving the facial nerve, which can precede the development of other NF2 manifestations. In 3 to 5 percent of adults, a more severe polyneuropathy not directly related to tumors is seen, and this can progress to severe muscle wasting [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/1,2,39\" class=\"abstract_t\">1,2,39</a>].</p><p class=\"headingAnchor\" id=\"H11\"><span class=\"h2\">Ophthalmic manifestations</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Patients with NF2 may have visual impairment due to cataracts, optic nerve meningiomas, retinal hamartomas, and epiretinal membrane [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/1,2,23,40\" class=\"abstract_t\">1,2,23,40</a>]. Cataracts are seen in 60 to 80 percent of cases and typically are manifested as posterior subcapsular lenticular opacities.</p><p>Development of cataracts can lead to visual abnormalities in early childhood in those with an NF2 mutation. In addition, particular attention is required to differentiate optic nerve meningiomas or hamartomas from retinoblastoma. (See <a href=\"topic.htm?path=retinoblastoma-clinical-presentation-evaluation-and-diagnosis#H6\" class=\"medical medical_review\">&quot;Retinoblastoma: Clinical presentation, evaluation, and diagnosis&quot;, section on 'Clinical presentation'</a>.)</p><p class=\"headingAnchor\" id=\"H12\"><span class=\"h2\">Cutaneous manifestations</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Approximately 70 percent of patients with NF2 have cutaneous manifestations, although only 10 percent have more than ten skin tumors [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/1\" class=\"abstract_t\">1</a>]. These skin lesions can take several forms:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Plaque-like lesions, which are intracutaneous and slightly raised [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/11\" class=\"abstract_t\">11</a>]. These may be more pigmented than the surrounding skin and may be associated with increased hair.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Subcutaneous nodules can often be palpated, sometimes along the course of a peripheral nerve. These tumors represent a swelling of the nerve.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Intracutaneous tumors, similar to those observed in patients with NF1, are also seen occasionally. These tumors generally represent schwannomas rather than neurofibromas.</p><p/><p class=\"headingAnchor\" id=\"H13\"><span class=\"h1\">DIAGNOSIS</span></p><p class=\"headingAnchor\" id=\"H14\"><span class=\"h2\">Clinical criteria</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Clinical criteria for neurofibromatosis type 2 (NF2) were initially established by an NIH consensus conference [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/41\" class=\"abstract_t\">41</a>]. These were subsequently modified into the Manchester criteria, which substantially improved the sensitivity for making the diagnosis without affecting specificity [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/20,42\" class=\"abstract_t\">20,42</a>].</p><p>Further revisions to the Manchester criteria now take into account the possibility that unilateral vestibular schwannomas may be due to <em>LZTR1</em> germline mutations (ie, schwannomatosis) rather than NF2 (see <a href=\"topic.htm?path=schwannomatosis\" class=\"medical medical_review\">&quot;Schwannomatosis&quot;</a>), and the diminishing likelihood of NF2 in patients with vestibular schwannomas diagnosed after 70 years of age [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/43,44\" class=\"abstract_t\">43,44</a>].</p><p>The clinical diagnosis of NF2 is based upon the presence of any ONE of the following criteria [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/44\" class=\"abstract_t\">44</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Bilateral vestibular schwannomas before age 70 years</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Unilateral vestibular schwannoma before age 70 years AND first-degree relative with NF2</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Any two of the following: meningioma, non-vestibular schwannoma, neurofibroma, glioma, cerebral calcification, cataract; AND</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>First-degree relative with NF2 OR</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Unilateral vestibular schwannoma AND negative <em>LZTR1</em> testing (if two or more non-intradermal schwannomas)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Multiple meningiomas AND:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Unilateral vestibular schwannoma OR</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Any two of the following: non-vestibular schwannoma, neurofibroma, glioma, cerebral calcification, cataract</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Constitutional or mosaic pathogenic <em>NF2</em> gene mutation from the blood or by the identification of an identical mutation from two separate tumors in the same individual</p><p/><p class=\"headingAnchor\" id=\"H15\"><span class=\"h2\">Screening for NF2</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>There is a high frequency of de novo NF2 cases, and patients may present before the clinical diagnostic criteria are fulfilled. Early identification of patients who have NF2 is important to minimize the complications associated with disease manifestations.</p><p>Evaluation for NF2 is recommended in the presence of any of the following [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/45,46\" class=\"abstract_t\">45,46</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A first-degree relative with NF2 (ie, affected parent, sibling, or offspring)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Multiple spinal tumors (schwannomas, meningiomas)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Cutaneous schwannomas</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>An apparently sporadic vestibular schwannoma in an individual younger than 30 years of age</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A solitary meningioma or non-vestibular schwannoma in an individual younger than 25 years of age [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/47\" class=\"abstract_t\">47</a>]</p><p/><p>The role of mutation screening for NF2 in all patients with a unilateral vestibular schwannoma is less certain. Although these patients appear to be at increased risk for the development of NF2, routine screening for germline mutations does not appear to be indicated except in those less than 30 years of age [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/45,46\" class=\"abstract_t\">45,46</a>].</p><p>For individuals suspected of having NF2, the initial evaluation should include a detailed clinical and family history, careful cutaneous and eye examinations, and magnetic resonance imaging (MRI) of the craniospinal axis [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/1\" class=\"abstract_t\">1</a>]. For individuals with a positive family history that includes identification of an <em>NF2</em> mutation, molecular testing for that mutation is indicated.</p><p class=\"headingAnchor\" id=\"H16\"><span class=\"h2\">Differential diagnosis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The major entities in the differential diagnosis of NF2 are sporadic vestibular schwannomas, neurofibromatosis type 1 (NF1), schwannomatosis, and a familial syndrome of multiple meningiomas [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/2\" class=\"abstract_t\">2</a>]. Mutations in the <em>LZTR1</em> gene, the second schwannomatosis gene after <em>SMARCB1</em>, have now been shown to also cause vestibular schwannomas and therefore cause the greatest diagnostic overlap [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/48\" class=\"abstract_t\">48</a>]. &#160; </p><p class=\"headingAnchor\" id=\"H17\"><span class=\"h3\">Sporadic vestibular schwannomas</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Sporadic vestibular schwannomas are relatively common in the general population. Although these tumors are unilateral, their diagnosis can cause confusion in some cases. (See <a href=\"topic.htm?path=vestibular-schwannoma-acoustic-neuroma\" class=\"medical medical_review\">&quot;Vestibular schwannoma (acoustic neuroma)&quot;</a>.)</p><p>The possibility that a unilateral vestibular schwannoma represents the first manifestation of NF2 is related to the age of the patient. For younger individuals who are less than 30 years of age, there is a substantial risk of developing a contralateral vestibular schwannoma, and patients should be monitored carefully for that possibility. Even with a negative family history these may represent a de novo somatic mutation with mosaicism [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/46,49\" class=\"abstract_t\">46,49</a>]. The likelihood that an individual diagnosed with a vestibular schwannoma after the age of 30 will have NF2 is minimal.</p><p>In patients with a unilateral vestibular schwannoma and multiple noncutaneous schwannomas, schwannomatosis due to mutations in <em>LZTR1</em> must also be considered. (See <a href=\"#H19\" class=\"local\">'Schwannomatosis'</a> below.)</p><p class=\"headingAnchor\" id=\"H19\"><span class=\"h3\">Schwannomatosis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Schwannomatosis is a rare sporadic or familial form of neurofibromatosis characterized by multiple noncutaneous peripheral and intracranial schwannomas in the absence of bilateral vestibular schwannomas. (See <a href=\"topic.htm?path=schwannomatosis\" class=\"medical medical_review\">&quot;Schwannomatosis&quot;</a>.)</p><p>Schwannomatosis is associated with mutations in the <em>SMARCB1</em> and <em>LZTR1</em> genes, which are also located on chromosome 22. The schwannomas seen in this entity contain somatic mutations in the <em>NF2</em> gene, but such mutations are not present in the germline. (See <a href=\"topic.htm?path=schwannomatosis#H9166943\" class=\"medical medical_review\">&quot;Schwannomatosis&quot;, section on 'Pathology and pathogenesis'</a>.)</p><p class=\"headingAnchor\" id=\"H71633524\"><span class=\"h3\">Neurofibromatosis type 1</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>NF2 and NF1 are caused by mutations in genes on different chromosomes. Nonetheless, partial overlap in the clinical manifestations of these inherited disorders can occasionally lead to confusion. (See <a href=\"topic.htm?path=neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis\" class=\"medical medical_review\">&quot;Neurofibromatosis type 1 (NF1): Pathogenesis, clinical features, and diagnosis&quot;</a>.)</p><p>Key differences between NF1 and NF2 include:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Lisch nodules (raised, pigmented hamartomas of the iris) are characteristic of NF1 and are not seen in significant numbers in NF2.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The schwannomas associated with NF2 rarely, if ever, undergo malignant transformation into a neurofibrosarcoma (malignant peripheral nerve sheath tumor).</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The &quot;dumbbell&quot; spinal root tumors that are seen with both NF2 and NF1 are schwannomas in NF2 and neurofibromas in NF1.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>NF2 is not associated with the cognitive impairment that is often seen with NF1.</p><p/><p class=\"headingAnchor\" id=\"H20\"><span class=\"h3\">Familial meningioma</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Familial meningioma is a rare disorder with only a few families described in the literature. This entity is not associated with abnormalities of the <em>NF2</em> gene. </p><p>Multiple meningiomas usually occur in older adults. The occurrence of a single meningioma in a patient less than 25 years of age should prompt evaluation for an underlying genetic disorder [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/34\" class=\"abstract_t\">34</a>].</p><p class=\"headingAnchor\" id=\"H21\"><span class=\"h1\">PATIENT MANAGEMENT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The management of patients with NF2 is complex, and involves multiple disciplines to prevent or treat the various complications that may develop. Whenever possible, patients should be cared for by a multidisciplinary team with expertise in the care of NF2 affected individuals and families [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/50\" class=\"abstract_t\">50</a>]. Multidisciplinary teams should include, at a minimum, a neurosurgeon, neuro-otologist, neuroradiologist, neurologist, audiologist, specialist nurse, and geneticist.</p><p class=\"headingAnchor\" id=\"H1135375976\"><span class=\"h2\">Tumor surveillance and follow-up</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>For individuals known to harbor an <em>NF2</em> mutation, follow-up should include [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/1,2,50\" class=\"abstract_t\">1,2,50</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Annual history and physical examination, including:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Audiology with measurement of pure-tone thresholds and word recognition scores</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Ophthalmologic evaluation</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Cutaneous examination</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Annual brain MRI, beginning at 10 years of age. If baseline imaging shows no characteristic sites of involvement, frequency can be reduced to every two years. If tumors are detected, brain MRI should be performed twice yearly in the first year, then annually. Brain MRI protocol should include high-resolution (1 to 3 mm slice thickness) post-contrast imaging through the internal auditory meatus, preferably in at least two orthogonal planes.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Surveillance spinal MRI every 24 to 36 months beginning at 10 years of age. The interval between scans may be reduced to every three to five years if there is no disease detected on baseline imaging. If tumors are detected, imaging should be repeated in six months to evaluate tumor growth rate.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Whole body MRI, including brain and spine, is used at some centers for surveillance.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>18F-fluorodeoxyglucose positron emission tomography (FDG-PET) is not recommended for routine screening, as the risk of malignant peripheral nerve sheath tumor (MPNST) is extremely small in an unirradiated patient with NF2. In addition, FDG-PET does not discriminate well between a cellular schwannoma and MPNST.</p><p/><p class=\"headingAnchor\" id=\"H22\"><span class=\"h2\">Treatment of vestibular schwannomas</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The goal of treatment for vestibular schwannomas in individuals with NF2 is preservation of function and maintenance of quality of life [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/1\" class=\"abstract_t\">1</a>]. As such, the identification of a tumor per se is not an indication for treatment and the potential benefits must be balanced against the risks of active intervention.</p><p>Treatment is generally indicated when there is a risk of brainstem compression, deterioration of hearing, <span class=\"nowrap\">and/or</span> facial nerve dysfunction [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/2\" class=\"abstract_t\">2</a>]. If treatment is required in patients with NF2, vestibular schwannomas are generally managed surgically. In this setting, surgery can be more complex than with sporadic tumors, since NF2 tumors are often multifocal [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/27,51\" class=\"abstract_t\">27,51</a>]. These tumors may extend to involve fibers of the facial nerve and there is a significant risk of damage to the facial nerve during surgery [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/1\" class=\"abstract_t\">1</a>]. This is particularly problematic, since the facial nerve controls the blink reflex and innervates the lacrimal gland. Loss of the blink reflex or loss of tearing may complicate other eye problems. (See <a href=\"#H11\" class=\"local\">'Ophthalmic manifestations'</a> above.)</p><p>Stereotactic radiosurgery and stereotactic radiotherapy have become important modalities in the treatment of appropriately selected patients with sporadic vestibular schwannomas. Such patients are generally much older than those with NF2 and have unilateral tumors. (See <a href=\"topic.htm?path=vestibular-schwannoma-acoustic-neuroma\" class=\"medical medical_review\">&quot;Vestibular schwannoma (acoustic neuroma)&quot;</a>.)</p><p>The role of radiation therapy in managing vestibular schwannomas in patients with NF2 is less clear [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/52-55\" class=\"abstract_t\">52-55</a>]. Reports using radiation in patients with NF2 have shown variable outcomes, and long-term follow-up is lacking. Furthermore, surgical resection may be more difficult following stereotactic radiosurgery. There are also concerns that such patients may have an increased risk of secondary malignancies [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/56-58\" class=\"abstract_t\">56-58</a>]. The risk of second malignancies may also be increased with fractionated radiation therapy, with one report of a rhabdomyosarcoma occurring in the radiation field in an NF2 patient [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/59\" class=\"abstract_t\">59</a>].</p><p>For patients with severe hearing impairment, strategies such as cochlear or brainstem implants may offer some benefit [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/60\" class=\"abstract_t\">60</a>]. (See <a href=\"topic.htm?path=hearing-amplification-in-adults#H11\" class=\"medical medical_review\">&quot;Hearing amplification in adults&quot;, section on 'Cochlear implants'</a>.)</p><p>Targeted therapies are an area of active investigation. (See <a href=\"#H25\" class=\"local\">'Targeted therapy'</a> below.)</p><p class=\"headingAnchor\" id=\"H23\"><span class=\"h2\">Meningioma management</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Meningiomas can arise both at intracranial sites and as intradural, extramedullary sites in the spinal cord. (See <a href=\"topic.htm?path=epidemiology-pathology-clinical-features-and-diagnosis-of-meningioma#H12\" class=\"medical medical_review\">&quot;Epidemiology, pathology, clinical features, and diagnosis of meningioma&quot;, section on 'Clinical presentation'</a>.)</p><p>Meningiomas are managed surgically when possible in patients with NF2. Radiation therapy has been used in patients whose tumors are not surgically accessible or in those in whom only a partial resection is possible [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/61\" class=\"abstract_t\">61</a>]. However, long-term follow-up is lacking in this population. As with the use of radiation in patients with vestibular schwannomas, there is concern about the development of secondary neoplasia. (See <a href=\"topic.htm?path=spinal-cord-tumors#H16\" class=\"medical medical_review\">&quot;Spinal cord tumors&quot;, section on 'Meningioma'</a>.)</p><p class=\"headingAnchor\" id=\"H24\"><span class=\"h2\">Intramedullary spinal tumors</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Approximately 75 percent of intramedullary spinal tumors are grade I or II ependymomas. These are often diagnosed with screening imaging studies and usually grow very slowly without symptoms for a prolonged period. Careful neurologic surveillance for evidence of progression is indicated in this situation. If symptoms require intervention, which is relatively uncommon, treatment is generally surgical resection rather than radiation therapy [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/62\" class=\"abstract_t\">62</a>]. There is some evidence that cystic elements of the tumors respond to <a href=\"topic.htm?path=bevacizumab-including-biosimilars-of-bevacizumab-drug-information\" class=\"drug drug_general\">bevacizumab</a> [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/63\" class=\"abstract_t\">63</a>].</p><p class=\"headingAnchor\" id=\"H25\"><span class=\"h2\">Targeted therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The <em>NF2</em> gene product appears to affect multiple molecular pathways involved in cell growth. An understanding of this provides a potential opportunity for targeted therapy in the treatment of NF2-related tumors.</p><p>Case reports and case series have reported that <a href=\"topic.htm?path=bevacizumab-including-biosimilars-of-bevacizumab-drug-information\" class=\"drug drug_general\">bevacizumab</a>, a monoclonal antibody against vascular endothelial growth factor (VEGF), can induce both tumor regression and hearing improvement in patients with NF2-associated vestibular schwannomas [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/64-69\" class=\"abstract_t\">64-69</a>]. In a series of 31 patients with progressing vestibular schwannomas, a radiographic response (defined as &ge;20 percent decrease in tumor volume) occurred in 55 percent of target tumors [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/66\" class=\"abstract_t\">66</a>]. Improvements in hearing were noted in 57 percent of ears associated with target vestibular schwannomas [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/66\" class=\"abstract_t\">66</a>]. A smaller prospective study confirmed durable hearing response in 36 percent of 14 patients [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/68\" class=\"abstract_t\">68</a>]. Early changes on dynamic contrast-enhanced MRI appear to be predictive of tumor response [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/68,70\" class=\"abstract_t\">68,70</a>].</p><p>In contrast, there is little evidence that <a href=\"topic.htm?path=bevacizumab-including-biosimilars-of-bevacizumab-drug-information\" class=\"drug drug_general\">bevacizumab</a> has activity in NF2-related meningiomas [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/71\" class=\"abstract_t\">71</a>]. </p><p>There are mixed reports on the efficacy of <a href=\"topic.htm?path=everolimus-drug-information\" class=\"drug drug_general\">everolimus</a>, an oral inhibitor of the mammalian target of rapamycin complex 1 (mTORC1), for progressive vestibular schwannomas in patients with NF2 [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/72,73\" class=\"abstract_t\">72,73</a>]. <a href=\"topic.htm?path=lapatinib-drug-information\" class=\"drug drug_general\">Lapatinib</a> showed evidence of objective activity in 4 out of 17 patients with NF2-related progressive vestibular schwannoma in a small phase II trial [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/74\" class=\"abstract_t\">74</a>], whereas <a href=\"topic.htm?path=erlotinib-drug-information\" class=\"drug drug_general\">erlotinib</a> was not effective in a retrospective series that included 11 patients with NF2 [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/75\" class=\"abstract_t\">75</a>].</p><p class=\"headingAnchor\" id=\"H26\"><span class=\"h2\">Screening of at-risk family members</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>For families in which there is documented index case of NF2, screening of at-risk family members is important so that a diagnosis can be established in affected individuals as early as possible [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/1\" class=\"abstract_t\">1</a>].</p><p>When a specific mutation has been identified in the index case, this information provides a 100 percent specific marker to test other family members. Prenatal testing is possible in settings where a known mutation has been identified [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/2\" class=\"abstract_t\">2</a>]. However, mutation screening is not 100 percent sensitive in patients with NF2.</p><p>For children who have not inherited NF2, no further testing or prospective evaluation is necessary. A detailed protocol for at risk relatives has been published [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/45\" class=\"abstract_t\">45</a>]. Tumor surveillance and follow-up for individuals with an <em>NF2</em> mutation is reviewed above. (See <a href=\"#H1135375976\" class=\"local\">'Tumor surveillance and follow-up'</a> above.)</p><p class=\"headingAnchor\" id=\"H27\"><span class=\"h1\">PROGNOSIS AND NATURAL HISTORY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Individuals typically present with symptoms due to the NF2-related tumors around age 20 years [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/20\" class=\"abstract_t\">20</a>]. The diagnosis of NF2 in children is often delayed, since the earliest manifestations may be skin tumors and ocular findings [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/26,76\" class=\"abstract_t\">26,76</a>]. Rare patients are diagnosed as late as the eighth decade of life with unusually indolent tumor growth patterns [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/77\" class=\"abstract_t\">77</a>].</p><p>Despite surveillance for the development of tumors in patients with NF2 and the aggressive management of any abnormalities that are detected, NF2 is associated with substantial morbidity and shortened survival [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/1\" class=\"abstract_t\">1</a>].</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The vestibular schwannomas associated with NF2 are more difficult to manage than their sporadic counterparts. In NF2 the lesions are often multifocal, and histologically, these are less vascular and more lobular [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/78\" class=\"abstract_t\">78</a>]. Because of this and the bilaterality of the tumors, the majority of patients eventually become completely deaf.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Poor balance due to eighth nerve involvement, visual problems, and muscle weakness can all contribute to immobility and many patients become wheelchair bound in early adulthood.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Overall survival appears to be shortened in patients with NF2 due to complications of their tumors. In studies from the 1970s and 1980s, the actuarial survival after establishing the diagnosis was 15 years, with an average age at death of 36 years [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/20,79,80\" class=\"abstract_t\">20,79,80</a>]. Earlier diagnosis and improved improvements in treatment may have improved outcomes [<a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/81,82\" class=\"abstract_t\">81,82</a>].</p><p/><p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\"><span class=\"h1\">INFORMATION FOR PATIENTS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>UpToDate offers two types of patient education materials, &quot;The Basics&quot; and &quot;Beyond the Basics.&quot; The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &quot;patient info&quot; and the keyword(s) of interest.) </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Basics topic (see <a href=\"topic.htm?path=vestibular-schwannoma-acoustic-neuroma-the-basics\" class=\"medical medical_basics\">&quot;Patient education: Vestibular schwannoma (acoustic neuroma) (The Basics)&quot;</a>)</p><p/><p class=\"headingAnchor\" id=\"H28\"><span class=\"h1\">SUMMARY</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Neurofibromatosis type 2 (NF2) is a dominantly inherited syndrome that causes multiple tumors of the nervous system in affected individuals. NF2 is due to abnormalities in the <em>NF2</em> gene, which produces merlin, a cell membrane-related protein that acts as a tumor suppressor. (See <a href=\"#H2\" class=\"local\">'Molecular pathogenesis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The clinical manifestations of NF2 include bilateral vestibular schwannomas in almost all patients. Other commonly observed nervous system tumors include intracranial meningiomas, schwannomas of other cranial nerves, and spinal tumors (especially schwannomas of the dorsal nerve roots, meningiomas, and ependymomas). Neuropathies and ocular and cutaneous manifestations are also frequent. (See <a href=\"#H6\" class=\"local\">'Clinical features'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The clinical diagnosis of NF2 is based upon the National Institutes of Health consensus criteria as subsequently modified in the Manchester criteria. The differential diagnosis includes sporadic unilateral vestibular schwannomas, schwannomatosis, neurofibromatosis type 1, and familial meningiomas. (See <a href=\"#H13\" class=\"local\">'Diagnosis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Although the management of the various manifestations of NF2 is similar to that for sporadic tumors of the same type, multidisciplinary team management is required to minimize disabilities and avoid potential morbidity caused by treatment. (See <a href=\"#H21\" class=\"local\">'Patient management'</a> above.)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/1\" class=\"nounderline abstract_t\">Evans DG. Neurofibromatosis type 2 (NF2): a clinical and molecular review. Orphanet J Rare Dis 2009; 4:16.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/2\" class=\"nounderline abstract_t\">Evans DG. Neurofibromatosis 2 [Bilateral acoustic neurofibromatosis, central neurofibromatosis, NF2, neurofibromatosis type II]. Genet Med 2009; 11:599.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/3\" class=\"nounderline abstract_t\">Asthagiri AR, Parry DM, Butman JA, et al. Neurofibromatosis type 2. Lancet 2009; 373:1974.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/4\" class=\"nounderline abstract_t\">Seizinger BR, Martuza RL, Gusella JF. Loss of genes on chromosome 22 in tumorigenesis of human acoustic neuroma. Nature 1986; 322:644.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/5\" class=\"nounderline abstract_t\">Rouleau GA, Merel P, Lutchman M, et al. Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2. Nature 1993; 363:515.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/6\" class=\"nounderline abstract_t\">Trofatter JA, MacCollin MM, Rutter JL, et al. A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell 1993; 72:791.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/7\" class=\"nounderline abstract_t\">Evans DG, Ramsden RT, Shenton A, et al. Mosaicism in neurofibromatosis type 2: an update of risk based on uni/bilaterality of vestibular schwannoma at presentation and sensitive mutation analysis including multiple ligation-dependent probe amplification. J Med Genet 2007; 44:424.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/8\" class=\"nounderline abstract_t\">Kluwe L, Mautner V, Heinrich B, et al. Molecular study of frequency of mosaicism in neurofibromatosis 2 patients with bilateral vestibular schwannomas. J Med Genet 2003; 40:109.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/9\" class=\"nounderline abstract_t\">Moyhuddin A, Baser ME, Watson C, et al. Somatic mosaicism in neurofibromatosis 2: prevalence and risk of disease transmission to offspring. J Med Genet 2003; 40:459.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/10\" class=\"nounderline abstract_t\">Evans DG, Wallace AJ, Wu CL, et al. Somatic mosaicism: a common cause of classic disease in tumor-prone syndromes? Lessons from type 2 neurofibromatosis. Am J Hum Genet 1998; 63:727.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/11\" class=\"nounderline abstract_t\">Castellanos E, Plana A, Carrato C, et al. Early Genetic Diagnosis of Neurofibromatosis Type 2 From Skin Plaque Plexiform Schwannomas in Childhood. JAMA Dermatol 2018; 154:341.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/12\" class=\"nounderline abstract_t\">Selvanathan SK, Shenton A, Ferner R, et al. Further genotype--phenotype correlations in neurofibromatosis 2. Clin Genet 2010; 77:163.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/13\" class=\"nounderline abstract_t\">Smith MJ, Higgs JE, Bowers NL, et al. Cranial meningiomas in 411 neurofibromatosis type 2 (NF2) patients with proven gene mutations: clear positional effect of mutations, but absence of female severity effect on age at onset. J Med Genet 2011; 48:261.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/14\" class=\"nounderline abstract_t\">Hexter A, Jones A, Joe H, et al. Clinical and molecular predictors of mortality in neurofibromatosis 2: a UK national analysis of 1192 patients. J Med Genet 2015; 52:699.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/15\" class=\"nounderline abstract_t\">Evans DG, Moran A, King A, et al. Incidence of vestibular schwannoma and neurofibromatosis 2 in the North West of England over a 10-year period: higher incidence than previously thought. Otol Neurotol 2005; 26:93.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/16\" class=\"nounderline abstract_t\">Evans DG, Howard E, Giblin C, et al. Birth incidence and prevalence of tumor-prone syndromes: estimates from a UK family genetic register service. Am J Med Genet A 2010; 152A:327.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/17\" class=\"nounderline abstract_t\">Antinheimo J, Sankila R, Carp&eacute;n O, et al. Population-based analysis of sporadic and type 2 neurofibromatosis-associated meningiomas and schwannomas. Neurology 2000; 54:71.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/18\" class=\"nounderline abstract_t\">Parry DM, Eldridge R, Kaiser-Kupfer MI, et al. Neurofibromatosis 2 (NF2): clinical characteristics of 63 affected individuals and clinical evidence for heterogeneity. Am J Med Genet 1994; 52:450.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/19\" class=\"nounderline abstract_t\">Mautner VF, Lindenau M, Baser ME, et al. The neuroimaging and clinical spectrum of neurofibromatosis 2. Neurosurgery 1996; 38:880.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/20\" class=\"nounderline abstract_t\">Evans DG, Huson SM, Donnai D, et al. A clinical study of type 2 neurofibromatosis. Q J Med 1992; 84:603.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/21\" class=\"nounderline abstract_t\">Bosch MM, Boltshauser E, Harpes P, Landau K. Ophthalmologic findings and long-term course in patients with neurofibromatosis type 2. Am J Ophthalmol 2006; 141:1068.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/22\" class=\"nounderline abstract_t\">Ragge NK, Baser ME, Riccardi VM, Falk RE. The ocular presentation of neurofibromatosis 2. Eye (Lond) 1997; 11 ( Pt 1):12.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/23\" class=\"nounderline abstract_t\">Ragge NK, Baser ME, Klein J, et al. Ocular abnormalities in neurofibromatosis 2. Am J Ophthalmol 1995; 120:634.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/24\" class=\"nounderline abstract_t\">MacCollin M, Mautner VF. The diagnosis and management of neurofibromatosis 2 in childhood. Semin Pediatr Neurol 1998; 5:243.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/25\" class=\"nounderline abstract_t\">Mautner VF, Lindenau M, Baser ME, et al. Skin abnormalities in neurofibromatosis 2. Arch Dermatol 1997; 133:1539.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/26\" class=\"nounderline abstract_t\">Evans DG, Birch JM, Ramsden RT. Paediatric presentation of type 2 neurofibromatosis. Arch Dis Child 1999; 81:496.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/27\" class=\"nounderline abstract_t\">Evans DG, Stivaros SM. Multifocality in neurofibromatosis type 2. Neuro Oncol 2015; 17:481.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/28\" class=\"nounderline abstract_t\">Abaza MM, Makariou E, Armstrong M, Lalwani AK. Growth rate characteristics of acoustic neuromas associated with neurofibromatosis type 2. Laryngoscope 1996; 106:694.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/29\" class=\"nounderline abstract_t\">Fisher LM, Doherty JK, Lev MH, Slattery WH. Concordance of bilateral vestibular schwannoma growth and hearing changes in neurofibromatosis 2: neurofibromatosis 2 natural history consortium. Otol Neurotol 2009; 30:835.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/30\" class=\"nounderline abstract_t\">Masuda A, Fisher LM, Oppenheimer ML, et al. Hearing changes after diagnosis in neurofibromatosis type 2. Otol Neurotol 2004; 25:150.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/31\" class=\"nounderline abstract_t\">Graamans K, Van Dijk JE, Janssen LW. Hearing deterioration in patients with a non-growing vestibular schwannoma. Acta Otolaryngol 2003; 123:51.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/32\" class=\"nounderline abstract_t\">Asthagiri AR, Vasquez RA, Butman JA, et al. Mechanisms of hearing loss in neurofibromatosis type 2. PLoS One 2012; 7:e46132.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/33\" class=\"nounderline abstract_t\">Goutagny S, Kalamarides M. Meningiomas and neurofibromatosis. J Neurooncol 2010; 99:341.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/34\" class=\"nounderline abstract_t\">Evans DG, Watson C, King A, et al. Multiple meningiomas: differential involvement of the NF2 gene in children and adults. J Med Genet 2005; 42:45.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/35\" class=\"nounderline abstract_t\">Perry A, Giannini C, Raghavan R, et al. Aggressive phenotypic and genotypic features in pediatric and NF2-associated meningiomas: a clinicopathologic study of 53 cases. J Neuropathol Exp Neurol 2001; 60:994.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/36\" class=\"nounderline abstract_t\">Larson JJ, van Loveren HR, Balko MG, Tew JM Jr. Evidence of meningioma infiltration into cranial nerves: clinical implications for cavernous sinus meningiomas. J Neurosurg 1995; 83:596.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/37\" class=\"nounderline abstract_t\">Patronas NJ, Courcoutsakis N, Bromley CM, et al. Intramedullary and spinal canal tumors in patients with neurofibromatosis 2: MR imaging findings and correlation with genotype. Radiology 2001; 218:434.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/38\" class=\"nounderline abstract_t\">Dow G, Biggs N, Evans G, et al. Spinal tumors in neurofibromatosis type 2. Is emerging knowledge of genotype predictive of natural history? J Neurosurg Spine 2005; 2:574.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/39\" class=\"nounderline abstract_t\">Sperfeld AD, Hein C, Schr&ouml;der JM, et al. Occurrence and characterization of peripheral nerve involvement in neurofibromatosis type 2. Brain 2002; 125:996.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/40\" class=\"nounderline abstract_t\">McLaughlin ME, Pepin SM, Maccollin M, et al. Ocular pathologic findings of neurofibromatosis type 2. Arch Ophthalmol 2007; 125:389.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/41\" class=\"nounderline abstract_t\">Neurofibromatosis. Conference statement. National Institutes of Health Consensus Development Conference. Arch Neurol 1988; 45:575.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/42\" class=\"nounderline abstract_t\">Gutmann DH, Aylsworth A, Carey JC, et al. The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. JAMA 1997; 278:51.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/43\" class=\"nounderline abstract_t\">Evans DG, Freeman S, Gokhale C, et al. Bilateral vestibular schwannomas in older patients: NF2 or chance? J Med Genet 2015; 52:422.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/44\" class=\"nounderline abstract_t\">Smith MJ, Bowers NL, Bulman M, et al. Revisiting neurofibromatosis type 2 diagnostic criteria to exclude LZTR1-related schwannomatosis. Neurology 2017; 88:87.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/45\" class=\"nounderline abstract_t\">Evans DG, Raymond FL, Barwell JG, Halliday D. Genetic testing and screening of individuals at risk of NF2. Clin Genet 2012; 82:416.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/46\" class=\"nounderline abstract_t\">Evans DG, Ramsden RT, Gokhale C, et al. Should NF2 mutation screening be undertaken in patients with an apparently isolated vestibular schwannoma? Clin Genet 2007; 71:354.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/47\" class=\"nounderline abstract_t\">Pathmanaban ON, Sadler KV, Kamaly-Asl ID, et al. Association of Genetic Predisposition With Solitary Schwannoma or Meningioma in Children and Young Adults. JAMA Neurol 2017; 74:1123.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/48\" class=\"nounderline abstract_t\">Smith MJ, Isidor B, Beetz C, et al. Mutations in LZTR1 add to the complex heterogeneity of schwannomatosis. Neurology 2015; 84:141.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/49\" class=\"nounderline abstract_t\">Mohyuddin A, Neary WJ, Wallace A, et al. Molecular genetic analysis of the NF2 gene in young patients with unilateral vestibular schwannomas. J Med Genet 2002; 39:315.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/50\" class=\"nounderline abstract_t\">Evans DGR, Salvador H, Chang VY, et al. Cancer and Central Nervous System Tumor Surveillance in Pediatric Neurofibromatosis 2 and Related Disorders. Clin Cancer Res 2017; 23:e54.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/51\" class=\"nounderline abstract_t\">Dewan R, Pemov A, Kim HJ, et al. Evidence of polyclonality in neurofibromatosis type 2-associated multilobulated vestibular schwannomas. Neuro Oncol 2015; 17:566.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/52\" class=\"nounderline abstract_t\">Kida Y, Kobayashi T, Tanaka T, Mori Y. Radiosurgery for bilateral neurinomas associated with neurofibromatosis type 2. Surg Neurol 2000; 53:383.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/53\" class=\"nounderline abstract_t\">Mathieu D, Kondziolka D, Flickinger JC, et al. Stereotactic radiosurgery for vestibular schwannomas in patients with neurofibromatosis type 2: an analysis of tumor control, complications, and hearing preservation rates. Neurosurgery 2007; 60:460.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/54\" class=\"nounderline abstract_t\">Roche PH, R&eacute;gis J, Pellet W, et al. [Neurofibromatosis type 2. Preliminary results of gamma knife radiosurgery of vestibular schwannomas]. Neurochirurgie 2000; 46:339.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/55\" class=\"nounderline abstract_t\">Rowe JG, Radatz MW, Walton L, et al. Clinical experience with gamma knife stereotactic radiosurgery in the management of vestibular schwannomas secondary to type 2 neurofibromatosis. J Neurol Neurosurg Psychiatry 2003; 74:1288.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/56\" class=\"nounderline abstract_t\">Baser ME, Evans DG, Jackler RK, et al. Neurofibromatosis 2, radiosurgery and malignant nervous system tumours. Br J Cancer 2000; 82:998.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/57\" class=\"nounderline abstract_t\">Evans DG, Birch JM, Ramsden RT, et al. Malignant transformation and new primary tumours after therapeutic radiation for benign disease: substantial risks in certain tumour prone syndromes. J Med Genet 2006; 43:289.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/58\" class=\"nounderline abstract_t\">Balasubramaniam A, Shannon P, Hodaie M, et al. Glioblastoma multiforme after stereotactic radiotherapy for acoustic neuroma: case report and review of the literature. Neuro Oncol 2007; 9:447.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/59\" class=\"nounderline abstract_t\">Carlson ML, Babovic-Vuksanovic D, Messiaen L, et al. Radiation-induced rhabdomyosarcoma of the brainstem in a patient with neurofibromatosis type 2. J Neurosurg 2010; 112:81.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/60\" class=\"nounderline abstract_t\">Neff BA, Wiet RM, Lasak JM, et al. Cochlear implantation in the neurofibromatosis type 2 patient: long-term follow-up. Laryngoscope 2007; 117:1069.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/61\" class=\"nounderline abstract_t\">Wentworth S, Pinn M, Bourland JD, et al. Clinical experience with radiation therapy in the management of neurofibromatosis-associated central nervous system tumors. Int J Radiat Oncol Biol Phys 2009; 73:208.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/62\" class=\"nounderline abstract_t\">Kalamarides M, Essayed W, Lejeune JP, et al. Spinal ependymomas in NF2: a surgical disease? J Neurooncol 2018; 136:605.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/63\" class=\"nounderline abstract_t\">Farschtschi S, Merker VL, Wolf D, et al. Bevacizumab treatment for symptomatic spinal ependymomas in neurofibromatosis type 2. Acta Neurol Scand 2016; 133:475.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/64\" class=\"nounderline abstract_t\">Mautner VF, Nguyen R, Kutta H, et al. Bevacizumab induces regression of vestibular schwannomas in patients with neurofibromatosis type 2. Neuro Oncol 2010; 12:14.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/65\" class=\"nounderline abstract_t\">Plotkin SR, Stemmer-Rachamimov AO, Barker FG 2nd, et al. Hearing improvement after bevacizumab in patients with neurofibromatosis type 2. N Engl J Med 2009; 361:358.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/66\" class=\"nounderline abstract_t\">Plotkin SR, Merker VL, Halpin C, et al. Bevacizumab for progressive vestibular schwannoma in neurofibromatosis type 2: a retrospective review of 31 patients. Otol Neurotol 2012; 33:1046.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/67\" class=\"nounderline abstract_t\">Hochart A, Gaillard V, Baroncini M, et al. Bevacizumab decreases vestibular schwannomas growth rate in children and teenagers with neurofibromatosis type 2. J Neurooncol 2015; 124:229.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/68\" class=\"nounderline abstract_t\">Blakeley JO, Ye X, Duda DG, et al. Efficacy and Biomarker Study of Bevacizumab for Hearing Loss Resulting From Neurofibromatosis Type 2-Associated Vestibular Schwannomas. J Clin Oncol 2016; 34:1669.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/69\" class=\"nounderline abstract_t\">Morris KA, Golding JF, Axon PR, et al. Bevacizumab in Neurofibromatosis type 2 (NF2) related vestibular schwannomas: a nationally coordinated approach to delivery and prospective evaluation. Neuro-Oncology Practice 2016.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/70\" class=\"nounderline abstract_t\">Li KL, Djoukhadar I, Zhu X, et al. Vascular biomarkers derived from dynamic contrast-enhanced MRI predict response of vestibular schwannoma to antiangiogenic therapy in type 2 neurofibromatosis. Neuro Oncol 2016; 18:275.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/71\" class=\"nounderline abstract_t\">Nunes FP, Merker VL, Jennings D, et al. Bevacizumab treatment for meningiomas in NF2: a retrospective analysis of 15 patients. PLoS One 2013; 8:e59941.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/72\" class=\"nounderline abstract_t\">Goutagny S, Raymond E, Esposito-Farese M, et al. Phase II study of mTORC1 inhibition by everolimus in neurofibromatosis type 2 patients with growing vestibular schwannomas. J Neurooncol 2015; 122:313.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/73\" class=\"nounderline abstract_t\">Karajannis MA, Legault G, Hagiwara M, et al. Phase II study of everolimus in children and adults with neurofibromatosis type 2 and progressive vestibular schwannomas. Neuro Oncol 2014; 16:292.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/74\" class=\"nounderline abstract_t\">Karajannis MA, Legault G, Hagiwara M, et al. Phase II trial of lapatinib in adult and pediatric patients with neurofibromatosis type 2 and progressive vestibular schwannomas. Neuro Oncol 2012; 14:1163.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/75\" class=\"nounderline abstract_t\">Plotkin SR, Halpin C, McKenna MJ, et al. Erlotinib for progressive vestibular schwannoma in neurofibromatosis 2 patients. Otol Neurotol 2010; 31:1135.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/76\" class=\"nounderline abstract_t\">Ruggieri M, Iannetti P, Polizzi A, et al. Earliest clinical manifestations and natural history of neurofibromatosis type 2 (NF2) in childhood: a study of 24 patients. Neuropediatrics 2005; 36:21.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/77\" class=\"nounderline abstract_t\">Goutagny S, Bah AB, Parfait B, et al. Neurofibromatosis type 2 in the elderly population: clinical and molecular features. Am J Med Genet A 2013; 161A:667.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/78\" class=\"nounderline abstract_t\">Sobel RA. Vestibular (acoustic) schwannomas: histologic features in neurofibromatosis 2 and in unilateral cases. J Neuropathol Exp Neurol 1993; 52:106.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/79\" class=\"nounderline abstract_t\">Evans DG, Huson SM, Donnai D, et al. A genetic study of type 2 neurofibromatosis in the United Kingdom. I. Prevalence, mutation rate, fitness, and confirmation of maternal transmission effect on severity. J Med Genet 1992; 29:841.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/80\" class=\"nounderline abstract_t\">Evans DG, Huson SM, Donnai D, et al. A genetic study of type 2 neurofibromatosis in the United Kingdom. II. Guidelines for genetic counselling. J Med Genet 1992; 29:847.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/81\" class=\"nounderline abstract_t\">Evans DG, Baser ME, O'Reilly B, et al. Management of the patient and family with neurofibromatosis 2: a consensus conference statement. Br J Neurosurg 2005; 19:5.</a></li><li><a href=\"https://www.uptodate.com/contents/neurofibromatosis-type-2/abstract/82\" class=\"nounderline abstract_t\">Baser ME, Friedman JM, Aeschliman D, et al. Predictors of the risk of mortality in neurofibromatosis 2. Am J Hum Genet 2002; 71:715.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 5206 Version 21.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H28\"><span>SUMMARY</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">MOLECULAR PATHOGENESIS</a><ul><li><a href=\"#H3\" id=\"outline-link-H3\">NF2 gene</a></li><li><a href=\"#H4\" id=\"outline-link-H4\">Genotype phenotype correlation</a></li></ul></li><li><a href=\"#H5\" id=\"outline-link-H5\">EPIDEMIOLOGY</a></li><li><a href=\"#H6\" id=\"outline-link-H6\">CLINICAL FEATURES</a><ul><li><a href=\"#H7\" id=\"outline-link-H7\">Vestibular schwannomas</a></li><li><a href=\"#H8\" id=\"outline-link-H8\">Meningiomas</a></li><li><a href=\"#H9\" id=\"outline-link-H9\">Spinal tumors</a></li><li><a href=\"#H10\" id=\"outline-link-H10\">Neuropathies</a></li><li><a href=\"#H11\" id=\"outline-link-H11\">Ophthalmic manifestations</a></li><li><a href=\"#H12\" id=\"outline-link-H12\">Cutaneous manifestations</a></li></ul></li><li><a href=\"#H13\" id=\"outline-link-H13\">DIAGNOSIS</a><ul><li><a href=\"#H14\" id=\"outline-link-H14\">Clinical criteria</a></li><li><a href=\"#H15\" id=\"outline-link-H15\">Screening for NF2</a></li><li><a href=\"#H16\" id=\"outline-link-H16\">Differential diagnosis</a><ul><li><a href=\"#H17\" id=\"outline-link-H17\">- Sporadic vestibular schwannomas</a></li><li><a href=\"#H19\" id=\"outline-link-H19\">- Schwannomatosis</a></li><li><a href=\"#H71633524\" id=\"outline-link-H71633524\">- Neurofibromatosis type 1</a></li><li><a href=\"#H20\" id=\"outline-link-H20\">- Familial meningioma</a></li></ul></li></ul></li><li><a href=\"#H21\" id=\"outline-link-H21\">PATIENT MANAGEMENT</a><ul><li><a href=\"#H1135375976\" id=\"outline-link-H1135375976\">Tumor surveillance and follow-up</a></li><li><a href=\"#H22\" id=\"outline-link-H22\">Treatment of vestibular schwannomas</a></li><li><a href=\"#H23\" id=\"outline-link-H23\">Meningioma management</a></li><li><a href=\"#H24\" id=\"outline-link-H24\">Intramedullary spinal tumors</a></li><li><a href=\"#H25\" id=\"outline-link-H25\">Targeted therapy</a></li><li><a href=\"#H26\" id=\"outline-link-H26\">Screening of at-risk family members</a></li></ul></li><li><a href=\"#H27\" id=\"outline-link-H27\">PROGNOSIS AND NATURAL HISTORY</a></li><li><a href=\"#PATIENT_INFORMATION\" id=\"outline-link-H277417459\">INFORMATION FOR PATIENTS</a></li><li><a href=\"#H28\" id=\"outline-link-H28\">SUMMARY</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=epidemiology-pathology-clinical-features-and-diagnosis-of-meningioma\" class=\"medical medical_review\">Epidemiology, pathology, clinical features, and diagnosis of meningioma</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=hearing-amplification-in-adults\" class=\"medical medical_review\">Hearing amplification in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=intradural-nerve-sheath-tumors\" class=\"medical medical_review\">Intradural nerve sheath tumors</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=neurofibromatosis-type-1-nf1-pathogenesis-clinical-features-and-diagnosis\" class=\"medical medical_review\">Neurofibromatosis type 1 (NF1): Pathogenesis, clinical features, and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=vestibular-schwannoma-acoustic-neuroma-the-basics\" class=\"medical medical_basics\">Patient education: Vestibular schwannoma (acoustic neuroma) (The Basics)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=retinoblastoma-clinical-presentation-evaluation-and-diagnosis\" class=\"medical medical_review\">Retinoblastoma: Clinical presentation, evaluation, and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=schwannomatosis\" class=\"medical medical_review\">Schwannomatosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=spinal-cord-tumors\" class=\"medical medical_review\">Spinal cord tumors</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=vestibular-schwannoma-acoustic-neuroma\" class=\"medical medical_review\">Vestibular schwannoma (acoustic neuroma)</a></li></ul></div></div>","javascript":null}